Search results for "Apparato cardiovascolare"

showing 10 items of 310 documents

Decision making and devices approach in a case of left main coronary artery thrombus.

2014

☆ This statement is to certify that all authors have seen being submitted, have contributed significantly to the w legitimacy of the data and its interpretation, and ag International Journal of Cardiology. We attest that the artic has not received prior publication and is not under elsewhere. We adhere to the statement of ethical pub (Shewan LG et al 2013 in press). ☆☆ On behalf of all co-authors, the corresponding author the submission. ⁎ Corresponding author at: Division of Cardiology II, D and Cardiovascular Diseases, University Hospital Paolo Gi 90127 Palermo, Italy. Tel.: +39 1 6554303; fax: +39 1 65 E-mail address: odisseos86@alice.it (V. Sucato).

medicine.medical_specialtyStatement (logic)business.industryGeneral surgeryInterpretation (philosophy)Left main coronary arteryIntravascular ultrasound; Left main coronary artery; Thrombusmedicine.diseaseUniversity hospitalSettore MED/11 - Malattie Dell'Apparato CardiovascolaremedicineIntravascular ultrasoundThrombusCardiology and Cardiovascular MedicinebusinessThrombus
researchProduct

Renal artery denervation for treating resistant hypertension: Definition of the disease, patient selection and description of the procedure

2012

Arterial hypertension is responsible for a significant burden of cardiovascular morbidity and mortality, worldwide. Although several rational and integrated pharmacological strategies are available, the control of high blood pressure still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on individual global cardiovascular risk, since it significantly increases the risk of developing hypertension-related macrovascular and microvascular complications. Arterial hypertension is arbitrarily defined as 'resistant' or 'refractory' when the recommended blood pressure goals (clinic blood pressure below…

medicine.medical_specialtySympathetic nervous systemSettore MED/09 - Medicina InternahypertensionDrug ResistanceFemoral arteryRisk AssessmentNephropathyPharmacotherapyRenal ArteryRisk Factorsmedicine.arteryInternal medicinemedicineInternal MedicineHumansArterial PressureRenal arterySympathectomyrenal artery denervationglobal cardiovascular riskantihypertensive therapyAntihypertensive AgentsSettore MED/14 - NefrologiaDenervationrefractory hypertensiontreatmentbusiness.industryPatient SelectionType 2 Diabetes Mellitusresistant hypertensionmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureBlood pressureTreatment Outcomeresistant hypertension refractory hypertension renal artery denervation antihypertensive therapy global cardiovascular risk.resistant-hypertension; treatment; hypertensionCardiologyCatheter AblationHypertension treatment; Resistant-hypertension treatment; Antihypertensive Agents; Humans; Hypertension; Patient Selection; Renal Artery; Risk Assessment; Risk Factors; Sympathectomy; Treatment Outcome; Arterial Pressure; Catheter Ablation; Drug Resistance; Internal Medicine; Cardiology and Cardiovascular MedicinebusinessCardiology and Cardiovascular Medicineresistant-hypertension
researchProduct

Thrombotic complications during overt hyperthyroidism

2012

medicine.medical_specialtyText miningbusiness.industryThrombosis hiperthyroidismEmergency MedicineInternal MedicinemedicineIntensive care medicinebusinessSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombotic complicationInternal and Emergency Medicine
researchProduct

Direct Oral Anticoagulants in the Setting of Catheter Ablation of Atrial Fibrillation: State of art

2021

Atrial fibrillation (AF) represents the arrhythmia of greatest clinical impact and catheter ablation of AF (CAAF) has become the most effective strategy for rhythm control in selected patients. Therefore, appropriate anticoagulation strategies are of paramount importance for patients undergoing CAAF, especially those at high risk, such those with high CHA2DS2VASc scores. Optimal management of anticoagulation before, during, and after CAAF is crucial. Several studies have evaluated the use of different anticoagulation strategies in the periprocedural period. Randomized controlled trial seem to suggest that in patients undergoing CAAF, uninterrupted (or minimally interrupted) direct oral anti…

medicine.medical_specialtyVitamin Kmedicine.medical_treatmentAdministration OralRhythm controlCatheter ablation030204 cardiovascular system & hematologyVitamin klaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineVitamin K/administration & dosagecatheter ablationmedicineHumansrisk factorsIn patientatrial fibrillation030212 general & internal medicineanticoagulationRandomized Controlled Trials as TopicAnticoagulants/administration & dosagebusiness.industryAnticoagulantsAtrial fibrillationGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareOptimal managementTreatment OutcomeState of artCardiologybusinessCardiology and Cardiovascular MedicineAtrial Fibrillation/complications
researchProduct

Dietary strategy for prevention and management of dyslipidemia: international guidelines

2012

Primary prevention of cardiovascular disease should begin with a detailed metabolic study of our patients who must follow a nutritional therapy. Recently, new guidelines ESC/EAS 2011 on the treatment of dyslipidemia have been drawn up, according to which it is possible to arrive at desirable values of cholesterol and triglycerides with a synergy between drug treatment and adequate diet therapy. At this time, Mediterranean diet has been undergoing a radical transformation: there is hyperalimentation of the Mediterranean diet in all its components. The effectiveness of the Mediterranean diet on the reduction of lipids has been demonstrated, and the problem is how to implement this diet in the…

medicine.medical_specialtyeducation.field_of_studySettore MED/09 - Medicina InternaNutrition and DieteticsMediterranean dietCholesterolDiet therapybusiness.industryEndocrinology Diabetes and MetabolismPopulationDiseasemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolarechemistry.chemical_compoundchemistryDiabetes mellitusmedicinePhysical therapyMedical nutrition therapyIntensive care medicineeducationbusinessDyslipidemiaDietDyslipidemia Prevention Guidelines EducationFood ScienceMediterranean Journal of Nutrition and Metabolism
researchProduct

Magnetic resonance in isolated noncompaction of the ventricular myocardium

2010

Abstract Non-compaction of the ventricular myocardium (LCVM) is a rare disorder of myocardial morphogenesis usually diagnosed in paediatric age. The diagnosis was echocardiographically made on the basis of a reported spongeous/compacted ratio >2 in one or more segments of the left ventricle during the diastolic period. We aimed to test the diagnostic accuracy of cardiovascular magnetic resonance (CMR) imaging in distinguishing pathological left ventricular non-compaction. Methods We collected a consecutive series of 8 patients, 5 males and 3 females, with a mean age of 14.9 years with non-compaction of left ventricular myocardium. All patients were admitted in our divisions of cardiology. I…

medicine.medical_specialtyeducation.field_of_studymedicine.diagnostic_testbusiness.industryPopulationDiastoleMagnetic resonance imagingResonance myocardiumSettore MED/11 - Malattie Dell'Apparato CardiovascolareApex (geometry)Ventricular myocardiummedicine.anatomical_structureVentricleNon-compaction of the ventricular myocardium (LCVM)Internal medicinecardiovascular systemLeft ventricular myocardiummedicineCardiologyCardiology and Cardiovascular MedicinebusinesseducationGradient echoCardiovascular magnetic resonance (CMR)
researchProduct

The Relationship between the Transforming Growth Factor β1 T29C Gene Polymorphism and Left Ventricular Geometry and Function in Hypertensive Subjects

2009

The distribution of the T29C TGFβ1 gene polymorphism was analyzed in 198 hypertensives with left ventricular hypertrophy (LVH) and in 235 hypertensives without LVH. Circulating TGFβ1 levels, procollagen type III levels, microalbuminuria, and left ventricular geometry and function were evaluated in all the hypertensives with LVH subgrouped according to T29C TGFβ1 gene polymorphism. Circulating TGFβ1 was evaluated by ELISA technique, procollagen type III by a specific radioimmunoassay, microalbuminuria by radioimmunoassay, and left ventricular geometry and function by echocardiography. All groups were comparable for gender, age, and sex. Regarding T29C TGFβ1 gene polymorphism, prevalence of T…

medicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaArticle SubjectLeft ventricular hypertrophyExcretionGene PolymorphismInternal medicineGenotypeInternal MedicinemedicineTransforming Growth Factor β1 T29C; Gene Polymorphism; Left Ventricular Geometry; Hypertensioncardiovascular diseasesTransforming Growth Factor β1 T29CEjection fractionbusiness.industryLeft Ventricular GeometryRadioimmunoassaymedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologylcsh:RC666-701HypertensionMicroalbuminuriaGene polymorphismbusinessResearch ArticleTransforming growth factorInternational Journal of Hypertension
researchProduct

Protrhombotic Effects of Contraceptives

2010

The use of oral contraceptives first became widespread some 40 years ago, and reports of an excess risk of cardiovascular disease among women who used these agents soon followed. Few drugs have been the object of such intensive epidemiological research, the outcome of which has provided clinicians with detailed information about risks not only of specific thrombotic diseases but also important non-contraceptive benefits from the pill. Recently, oral contraceptives have been classified by some according to "generation" (first, second, third, and most recently, fourth generation): first-generation formulations containing lynestrenol or norethindrone, second-generation formulations containing …

medicine.medical_specialtymedicine.drug_classLipid Metabolism DisordersMyocardial InfarctionPhysiologyGestodeneRisk AssessmentRisk FactorsDesogestrelInternal medicineDrug DiscoverymedicineHumansLevonorgestrelGlucose Metabolism DisordersVenous ThrombosisPharmacologyHemostasisbusiness.industryModels CardiovascularAtherosclerosisLipid MetabolismNorgestimateSettore MED/11 - Malattie Dell'Apparato CardiovascolareLynestrenolEndocrinologyEstrogenPillHypertensionFemaleRisk assessmentbusinessTrhombosis contraceptivesContraceptives Oralmedicine.drugCurrent Pharmaceutical Design
researchProduct

Treatment decision making in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: State of the art

2014

No abstract available

medicine.medical_specialtymedicine.medical_treatmentDecision MakingCardiomyopathySudden deathImplantable cardioverter-defibrillatorAntiarrhythmic drugs; Cardiac transplantation; Implantable cardioverter-defibrillator; Management; Radiofrequency catheter ablation; Sudden death; Arrhythmogenic Right Ventricular Dysplasia; Decision Making; HumansAntiarrhythmic drugs; Cardiac transplantation; Implantable cardioverter-defibrillator; Management; Radiofrequency catheter ablation; Sudden deathInternal medicinemedicineHumansIn patientIntensive care medicineArrhythmogenic Right Ventricular DysplasiaRadiofrequency catheter ablationbusiness.industrySudden deathImplantable cardioverter-defibrillatormedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareArrhythmogenic right ventricular dysplasiaAntiarrhythmic drugsManagementAntiarrhythmic drugRadiofrequency catheter ablationCardiologyCardiac transplantationTreatment decision makingCardiology and Cardiovascular Medicinebusiness
researchProduct

The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fr…

2019

Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on cardiac performance remains limited. We sought to evaluate the effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure and reduced ejection fraction (HFrEF). Methods: Sacubitril/valsartan was administered to 205 HFrEF patients. Results: Among 230 patients (mean age 59 &plusmn

medicine.medical_specialtymedicine.medical_treatmentheart failureHemodynamics030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciences0302 clinical medicinehemodynamicInternal medicinemedicineechocardiography030212 general & internal medicineEnalaprilremodelingEjection fractionbusiness.industryneprilysin inhibitionGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareValsartansacubitril/valsartanHeart failureCardiologyreduced ejection fractionDiureticbusinessNt-ProBNPSacubitril Valsartanmedicine.drugJournal of Clinical Medicine
researchProduct